Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03461952 | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)(NIMBLe) | terminated | Phase 2 | 4 | Canadian Cancer Trials GroupNETWORK | 2 | Feb 22, 2024 | clinicaltrials |
| NCT03573544 | This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | terminated | Phase 1 / Phase 2 | 54 | OBI Pharma, IncINDUSTRY | 2 | Feb 22, 2024 |
| clinicaltrials |
| NCT04165590 | Plasmodium Immunotherapy for Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04934514 | Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 97 | SUNHO(China)BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04984668 | A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors | unknown | Phase 1 / Phase 2 | 216 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | terminated | Phase 2 | 63 | Debiopharm International SAINDUSTRY | 23 | Feb 7, 2024 | clinicaltrials |
| NCT03838042 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | recruiting | Phase 1 / Phase 2 | 91 | University Hospital HeidelbergOTHER | 7 | Feb 7, 2024 | clinicaltrials |
| NCT04071756 | Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions | terminated | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05358379 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Feb 7, 2024 | clinicaltrials |
| NCT05430555 | A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors(IMAG1NE) | terminated | Phase 1 / Phase 2 | 23 | T-knife GmbHINDUSTRY | 5 | Feb 7, 2024 | clinicaltrials |
| NCT06245330 | A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT01311713 | Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 45 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Jan 25, 2024 | clinicaltrials |
| NCT06223308 | A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 54 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT04465760 | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy | terminated | Phase 2 | 9 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT05576961 | Safety and Efficacy of RX-af01 Combined With PD-1 Antibody | unknown | Phase 1 / Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02829723 | A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 192 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 18, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT06183736 | CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency | not yet recruiting | Phase 2 | 98 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT04407741 | Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02030067 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | completed | Phase 1 / Phase 2 | 127 | Processa PharmaceuticalsINDUSTRY | 1 | Dec 6, 2023 | clinicaltrials |
| NCT01190644 | Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors | terminated | Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05923008 | A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 182 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT06144723 | Study of HS-20105 for Injection in Patients With Advanced Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 402 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Nov 22, 2023 | clinicaltrials |
| NCT06132217 | A Study of Simmitinib Plus SG001 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 168 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT05920408 | Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Exscientia AI LimitedINDUSTRY | 2 | Nov 8, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06112041 | The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0) | not yet recruiting | Phase 2 | 29 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05255484 | Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 24 | LaNova Medicines LimitedINDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT06056323 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 71 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06092268 | A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 270 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Oct 23, 2023 | clinicaltrials |
| NCT03274661 | Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors | completed | Phase 2 | 52 | Baptist Health South FloridaOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT03253679 | AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06082557 | A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06082570 | A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06078670 | PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 96 | Fujian Cancer HospitalOTHER_GOV | 0 | Oct 12, 2023 | clinicaltrials |
| NCT04717674 | [18F]FPIA PET/CT Imaging in Patients With Solid Tumours([18F]FPIA) | unknown | Phase 2 | 21 | University College, LondonOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04171700 | A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes(LODESTAR) | terminated | Phase 2 | 83 | pharmaand GmbHINDUSTRY | 1 | Oct 2, 2023 | clinicaltrials |
| NCT01827384 | MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations | completed | Phase 2 | 208 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT06047860 | A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 22, 2024source: clinicaltrials